Iqvia initiated with an Outperform at Leerink

Leerink analyst Michael Cherny initiated coverage of Iqvia with an Outperform rating and $290 price target. The firm notes Iqvia is one of the market leaders in the contract research organization, or CRO, space, particularly in later-stage trials. Its leadership position is further augmented by its data assets, which aid biopharma customers in their clinical through commercial efforts, Leerink adds.